Modalités thérapeutiques du myélome multiple

Multiple myeloma (MM) is a malignant hemopathy characterised by the bone marrow involvement by clonal plasma cells. Despite the progress made with autologous stem cell transplantation (ASCT), the prognosis remains poor. In that context, the development of new molecules, such as thalidomide or its analogues (lenalidomide) and the first proteasome inhibitor, bortezomib, has recently improved the management of this hemopathy. We will review new strategies in MM, including updated development in ASCT and the role of innovative molecules in the management of this pathology. However, the majority of the patients are older and therapeutics must be adapted to this particular subgroup of patients.